Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

0(0%)

Results Posted

100%(3 trials)

Phase Distribution

Ph phase_4

33%

Ph phase_3

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 3Large-scale testing

2(66.7%)

Phase 4Post-market surveillance

1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 32 (66.7%)

Phase 41 (33.3%)

Trials by Status

completed3100%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_4

Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849)

NCT00536380

completedphase_3

Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)

NCT00405964

completedphase_3

Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)

NCT00406783

Clinical Trials (3)

Showing 3 of 3 trials

NCT00536380Phase 4

Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849)

Completed

NCT00405964Phase 3

Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)

Completed

NCT00406783Phase 3

Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3